4D Molecular Therapeutics (FDMT)

• Market cap: $182M
• 1 day: 0.26%
• 5 days: -5.30%
• 1 month: -13.05%
• 3 months: -32.36%
• 6 months: -65.80%
• Year to date: -32.59%
• 1 year: -88.30%
• 5 years: -90.30%
• 10 years: -90.30%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Employees: 227

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

132% more call options, than puts

Call options by funds: $858K | Put options by funds: $370K

19% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 27

16% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 44

4% more funds holding

Funds holding: 139 [Q3] → 144 (+5) [Q4]

10.29% less ownership

Funds ownership: 111.65% [Q3] → 101.37% (-10.29%) [Q4]

58% less capital invested

Capital invested by funds: $628M [Q3] → $262M (-$366M) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 53% upside
• Avg. target: $29 629% upside
• High target: $40 918% upside

6 analyst ratings

• positive: 5 83%
• neutral: 0 0%
• negative: 1 17%

B of A Securities Tazeen Ahmad 33% 1-year accuracy 12 / 36 met price target	918% upside $40	Buy Maintained	10 Mar 2025
Chardan Capital Geulah Livshits 19% 1-year accuracy 11 / 59 met price target	612% upside $28	Buy Maintained	4 Mar 2025
RBC Capital Luca Issi 20% 1-year accuracy 11 / 56 met price target	791% upside $35	Outperform Maintained	3 Mar 2025
HC Wainwright & Co. Matthew Caufield 42% 1-year accuracy 25 / 60 met price target	816% upside $36	Buy Reiterated	3 Mar 2025
Morgan Stanley Judah Frommer 45% 1-year accuracy 5 / 11 met price target	53% upside $6	Underweight Maintained	13 Jan 2025